Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Roswitha Forstpointner, Wolfgang Hiddemann, Christiane Pott et al.|Blood|2006Cited by 465
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemiaLeo Ruhnke, Christoph Röllig, Marius Bill et al.|Blood Advances|2024Cited by 17
Current treatment of mantle cell lymphoma: results of a national survey and consensus meetingMathias Witzens‐Harig, M. Dreyling, J. Atta et al.|Annals of Hematology|2012Cited by 13